Gravity Analytica

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

OPT 12.19.2024

SERA-AI Powered Highlights

Drug:sozinibercept sozinibercept

Diseases:wet age-related macular degeneration

Date of Upcoming Event:2025-01-15

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our OPT Tweets

About Gravity Analytica

Recent Filings

Business update to include masked Phase 3 patient demographics and baseline characteristics

Presentation onWednesday, January 15, 2025,5:15 PM PTinSan Francisco, California

MELBOURNE, AustraliaandPRINCETON, N.J.,Dec. 19, 2024(GLOBE NEWSWIRE) --Opthea Limited(ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced thatFrederic Guerard, PharmD, Chief Executive Officer, will present at the 43^rdAnnualJ.P. Morgan Healthcare ConferenceinSan Francisco, CaliforniaonWednesday, January 15, 2025at5:15 PM PT.

Dr. Guerardwill provide an update on the business, including masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials. Opthea’s executive team will attend the conference and be available for one-on-one meetingsJanuary 13-16, 2025.

The live webcast and presentation will be accessible on the “Events & Presentations” section of the Company’s website athttp://ir.opthea.com/, where the replay will be available for 30 days.

AboutOpthea

Opthea(ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe,NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website atwww.opthea.comand follow us onXandLinkedIn.

Authorized for release to ASX byFrederic Guerard, PharmD, CEO

Investor InquiriesPJ KelleherLifeSci Advisors, LLCEmail:pkelleher@lifesciadvisors.comPhone: 617-430-7579	Media InquiriesSilvana Guerci-LenaNorthStream Global PartnersEmail:silvana@nsgpllc.com

Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email:info@opthea.comWeb:www.opthea.com

Source:Opthea Limited

Source: Opthea Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com